William Blair Reduces Earnings Estimates for Stevanato Group

Stevanato Group S.p.A. (NYSE:STVN - Free Report) - William Blair reduced their Q1 2026 earnings estimates for shares of Stevanato Group in a research report issued to clients and investors on Friday, May 9th. William Blair analyst M. Larew now expects that the company will post earnings of $0.12 per share for the quarter, down from their previous forecast of $0.13. William Blair has a "Outperform" rating on the stock. The consensus estimate for Stevanato Group's current full-year earnings is $0.50 per share. William Blair also issued estimates for Stevanato Group's Q2 2026 earnings at $0.13 EPS, Q3 2026 earnings at $0.18 EPS and Q4 2026 earnings at $0.27 EPS.

Several other research analysts also recently issued reports on STVN. Stephens upgraded Stevanato Group to a "strong-buy" rating in a research report on Monday, April 21st. UBS Group decreased their price target on shares of Stevanato Group from $24.00 to $23.50 and set a "neutral" rating for the company in a research report on Friday, March 7th. Two research analysts have rated the stock with a hold rating, four have assigned a buy rating and one has given a strong buy rating to the company's stock. According to MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and a consensus target price of €25.70 ($28.88).

Stevanato Group Stock Performance

Shares of STVN stock traded up €0.76 ($0.85) during mid-day trading on Monday, hitting €24.42 ($27.44). The stock had a trading volume of 374,000 shares, compared to its average volume of 350,972. Stevanato Group has a fifty-two week low of €16.56 ($18.61) and a fifty-two week high of €24.90 ($27.98). The firm has a market cap of $7.40 billion, a PE ratio of 51.96, a PEG ratio of 7.18 and a beta of 0.51. The company has a debt-to-equity ratio of 0.22, a current ratio of 1.81 and a quick ratio of 1.21. The company's 50-day simple moving average is €21.30 and its 200-day simple moving average is €21.08.

Stevanato Group (NYSE:STVN - Get Free Report) last posted its earnings results on Thursday, March 6th. The company reported €0.20 ($0.22) EPS for the quarter, meeting analysts' consensus estimates of €0.20 ($0.22). The firm had revenue of €352.68 million for the quarter, compared to the consensus estimate of €346.26 million. Stevanato Group had a net margin of 10.47% and a return on equity of 9.86%.

Stevanato Group Increases Dividend

The firm also recently disclosed an annual dividend, which will be paid on Thursday, July 17th. Investors of record on Thursday, June 5th will be paid a $0.0613 dividend. This represents a dividend yield of 0.3%. The ex-dividend date of this dividend is Thursday, June 5th. This is a positive change from Stevanato Group's previous annual dividend of $0.05. Stevanato Group's payout ratio is presently 11.76%.

Institutional Inflows and Outflows

Institutional investors have recently bought and sold shares of the company. Whittier Trust Co. acquired a new stake in shares of Stevanato Group during the 1st quarter valued at about $27,000. Van Berkom & Associates Inc. acquired a new stake in shares of Stevanato Group in the 4th quarter valued at $39,000. Johnson Financial Group Inc. bought a new position in shares of Stevanato Group in the 4th quarter valued at about $41,000. Wells Fargo & Company MN lifted its stake in shares of Stevanato Group by 680.3% in the 4th quarter. Wells Fargo & Company MN now owns 3,246 shares of the company's stock valued at $71,000 after purchasing an additional 2,830 shares during the period. Finally, PNC Financial Services Group Inc. boosted its holdings in Stevanato Group by 1,457.6% during the fourth quarter. PNC Financial Services Group Inc. now owns 5,654 shares of the company's stock worth $123,000 after buying an additional 5,291 shares during the last quarter.

Stevanato Group Company Profile

Stevanato Group S.p.A. engages in the design, production, and distribution of products and processes to provide integrated solutions for bio-pharma and healthcare industries in Europe, the Middle East, Africa, North America, South America, and the Asia Pacific. The company operates in two segments, Biopharmaceutical and Diagnostic Solutions; and Engineering.